title: Enoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism: Initial Experience in a Single Center.
abstract: Rivaroxaban is a target-specific oral anticoagulant approved for the treatment of venous thromboembolism (VTE). On its major clinical trials, treatment was initiated directly with a 3-week dose of oral 15 mg twice daily followed by 20 mg every day for at least 3 months. We retrospectively evaluated an initial therapy for confirmed VTE with 1 to 18 days of enoxaparin (1 mg/kg twice daily parenteral) followed by oral rivaroxaban 20 mg every day. Of 49 patients, we found no symptomatic recurrence, no major bleeding, and only 1 clinically relevant nonmajor bleeding. We concluded in this pilot study that it is safe and effective to treat patients with enoxaparin course followed directly by a dose of 20 mg of rivaroxaban.
authors.affiliation: Division of Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil nwolosker@yahoo.com.br eduardoramacciotti@gmail.com.
authors.forename: Nelson
authors.initials: N
authors.lastname: Wolosker
authors.affiliation: Division of Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: Andrea Y M
authors.initials: AY
authors.lastname: Varella
authors.affiliation: Division of Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: Juliana M
authors.initials: JM
authors.lastname: Fukuda
authors.affiliation: Division of Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Teivelis
authors.affiliation: Division of Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: Sergio
authors.initials: S
authors.lastname: Kuzniec
authors.affiliation: Division of Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: Mariana
authors.initials: M
authors.lastname: Krutman
authors.affiliation: Division of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: João C de C
authors.initials: JC
authors.lastname: Guerra
authors.affiliation: Division of Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil nwolosker@yahoo.com.br eduardoramacciotti@gmail.com.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Ramacciotti
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017984:Enoxaparin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D035002:Lower Extremity / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D000069552:Rivaroxaban / Q000008:administration & dosage* / Q000009:adverse effects; D054556:Venous Thromboembolism / Q000188:drug therapy*
chemical_list: D017984:Enoxaparin; D000069552:Rivaroxaban
keywords: rivaroxaban; target-specific oral anticoagulants; venous thromboembolism